title: Targeted anti-HER2 cancer therapy in elderly women diagnosed with breast cancer.
abstract: Trastuzumab or lapatinib treatment with chemotherapy or hormonotherapy are the gold standard treatments for human epidermal growth factor receptor 2 (HER2)-positive breast cancer (early breast cancer or metastatic breast cancer). Older patients have been largely underrepresented in clinical trials, and few data on trastuzumab or lapatinib efficacy and toxicity have been reported for this subgroup. This article has reviewed the main articles that have analyzed these items.
authors: M J
authors: MJ
authors: Molina-Garrido
authors: C
authors: C
authors: Guillen-Ponce
authors: Consulta de Cancer en el Anciano, Seccion de Oncologia Medica, Hospital General Virgen de la Luz in Cuenca, Hermandad Donantes de Sangre Street, Cuenca, Spain. mjmolinagarrido@hotmail.com.
authors: A
authors: A
authors: Mora-Rufete
mesh_terms: D000368:Aged; D000375:Aging / Q000502:physiology; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D000077341:Lapatinib; D058990:Molecular Targeted Therapy; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000077341:Lapatinib; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human